Efficacy of Erlotinib Versus Vinorelbine Plus Cisplatin as Adjuvant Therapy for StageⅢA EGFR Mutation-Positive Non-Small Cell Lung Cancer

YAN Xiao-long; XIA Jin

doi:10.12019/j.issn.1671-5144.2019.01.012

YAN Xiao-long, XIA Jin. Efficacy of Erlotinib Versus Vinorelbine Plus Cisplatin as Adjuvant Therapy for StageⅢA EGFR Mutation-Positive Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2019, 19(1): 44-46. DOI: 10.12019/j.issn.1671-5144.2019.01.012

Citation:

YAN Xiao-long, XIA Jin. Efficacy of Erlotinib Versus Vinorelbine Plus Cisplatin as Adjuvant Therapy for StageⅢA EGFR Mutation-Positive Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2019, 19(1): 44-46. DOI: 10.12019/j.issn.1671-5144.2019.01.012

Citation:

YAN Xiao-long, XIA Jin. Efficacy of Erlotinib Versus Vinorelbine Plus Cisplatin as Adjuvant Therapy for StageⅢA EGFR Mutation-Positive Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2019, 19(1): 44-46. DOI: 10.12019/j.issn.1671-5144.2019.01.012

Efficacy of Erlotinib Versus Vinorelbine Plus Cisplatin as Adjuvant Therapy for StageⅢA EGFR Mutation-Positive Non-Small Cell Lung Cancer

Graphical Abstract

Abstract

FullText(HTML)

References (0)

Efficacy of Erlotinib Versus Vinorelbine Plus Cisplatin as Adjuvant Therapy for StageⅢA EGFR Mutation-Positive Non-Small Cell Lung Cancer

Catalog

Export File

Citation

Format

Content